Roberta A. Strohl

Sleep alterations in cancer patients

This multi-institutional sleep study involved two phases aimed at investigating sleep alterations in patients with any stage of breast and lung cancer. The first phase of this study used an 82-item, 20-minute telephone survey to elicit information regarding the impact of sleep disturbances on a convenience sample of 150 patients. Of these patients, 44% reported a sleep problem during the month before the interview. Significant relations included these: report of sleep problems prediagnosis over the past month (x = 5.82; p = 0.02), duration of sleep medication use and frequency of sleep problem (r = 0.58; p = 0.05), age and severity of sleep problems (r = 0.38; p = 0.05), and frequency and severity of the sleep problem over the past month (r = 0.21; p < 0.10). Communication with health care providers occurred in 16.6% of patients reporting a sleep disturbance. The second phase of this study explored the type, frequency, and severity of sleep problems and perceptions of causation, support, and methods of coping with the sleep problem. A qualitative approach to the problem was used in this phase. A one-time telephone interview of 42 patients, derived from a convenience sample, revealed a 45% prevalence of sleep problems a month before the interview. A qualitative analysis of the responses suggested that sleep problems are related to experiences of other symptoms and perceptions of cancer and treatment. Content analysis of the responses identified the following categories: figuring out the reason, seeking help, seeking support and relation to the overall cancer experience.

A prospective randomized trial comparing once-a-week vs daily radiation therapy for locally-advanced, non-metastatic, lung cancer: A preliminary report☆

This is the first report of an on-going Phase III protocol for patients with locally-advanced, non-metastatic, measurable lung cancer. The study randomizes two arms: 6000 rad using 500 rad fractions once a week (1 X W) for 12 weeks with spinal cord (SC) protection at 3000 rad; and 6000 rad using 200 rad fractions daily (5 X W) for 6 weeks with SC protection at 4500 rad. Both arms use an initially large loco-regional field that is further reduced when tumor doses reach 3000 rad in (1 X W) arm and 5000 rad in (5 X W) arm. The protocol was activated April 1982; as of August 1984, it had accrued 100 patients of whom 68 were evaluable [29 (1 X W) and 39 (5 X W)]. There have been no major differences in tumor responses or failure patterns between the (1 X W) and (5 X W) arms; response rates have been 69 and 64%; CR 31 and 20%; total incidence of local failures 20 and 23%; and overall incidence of distant failures 34 and 43%, respectively. The (1 X W) arm has been far better tolerated with 76% of its patients free of any esophagitis and 97% without weight loss, as compared to only 33 and 67% in the (5 X W), respectively. The (1 X W) arm has not conveyed loss in tumor control effectiveness, in-treatment progression, or higher incidence of distant spread. Subacute and chronic complications have been minimal with either treatment. No fatal or life-threatening toxicities have occurred; the incidence of severe complications has been 7% in the (1 X W) arm and 8% in the (5 X W) arm. Nevertheless, the number of patients alive and at risk greater than or equal to 12 months is still relatively small; definitive statements regarding very late toxic reactions cannot yet be made. Compared to their protocyptes [a (1 X W) Pilot Study and the 6000 rad/6 weeks arm of RTOG Protocol 73-01], results in the present protocol arms have not been different from what was expected. Once a week RT yields results that appear no different from those achieved with conventional RT in lung cancer.

Once-a-week vs conventional daily radiation treatment for lung cancer: Final report

This is the final report of a prospective randomized clinical trial which began in 1982 and explored once-a-week hypofractionation in lung cancer patients with unresectable, non-metastatic, measurable, loco-regionally advanced disease. Stratification to this protocol has been done by histology, stage, and performance status categories. Patients with ipsilateral supraclavicular and/or brain metastases as the only evidence of distant spread, have been included in the study, but were stratified and analyzed separately. The two protocol arms were: (I) Conventional daily radiation [5 x W]-5 daily fractions of 2 Gy each to a total dose of 60 Gy in 6 weeks, protecting the spinal (SC) at 45 Gy and (II) Once-a-week radiation [1 x W]-one weekly fraction of 5 Gy each to a total tumor dose of 60 Gy in 12 weeks protecting the SC at 30 Gy. A total of 150 patients have been entered. Of these, 30 pts. are inevaluable, but the reasons of non-compliance, progression of disease or death due to intercurrent disease were of equal incidence in both groups. Of the 120 evaluable patients, 63 were treated 5 x W and 57 with 1 x W therapy. Complete tumor responses are similar in both arms with 1 x W pts demonstrating a numerical advantage (26% vs 17%). The average follow-up of the entire series is 3 yrs with a range of 12-66 months. Survival data is comparable in both groups with the 12 and 24 month actuarial survival of 49% and 23% for the 5 x W arm and 59% and 29% for the 1 x W arm. 1 x W patients continue to show a better tolerance than 5 x W pts. There are sufficient long-term survivors in both arms to assess chronic toxicity. The number of patients alive at 12, 18, and 24 months were 25, 11, and 5 for the 5 x W arm and 29, 16, and 7 for the 1 x W arm. No significant differences in late reactions have been noted. The longest surviving patient in the 1 x W arm is now 48 months after treatment.

Nursing management of the patient with cancer experiencing taste changes.

Taste changes occur in patients with cancer as a result of both the disease process and therapy for the disease. Taste changes include alterations in the perception of bitter and sweet sensations and may involve meat aversions. Radiotherapy to the oral cavity causes a loss of taste related to radiation effects to the taste buds and salivary glands. Nursing management of the patient experiencing taste changes includes educating both the patient and family about taste changes and suggesting ways to maintain nutritional intake.

Radiation therapy in tumors of the central nervous system

OBJECTIVES To review the role of radiation therapy in the management of primary tumors of the central nervous system (CNS). DATA SOURCES Book chapters, review articles, and research studies. CONCLUSIONS Radiation therapy plays an important role in the management of primary and metastatic tumors of the CNS. Radiation and surgery are combined with curative intent for low-grade tumors. Cranial radiation may be used to prevent brain metastases, and palliative radiation may be used to alleviate symptoms. IMPLICATIONS FOR NURSING PRACTICE Helping patients with tumors of the CNS and their family members understand the anticipated side effects of the disease and the therapeutic goals of radiation therapy may help to alleviate anxiety and maintain an optimal quality of life during therapy.

Radiation therapy for head and neck cancers

ADIATION THERAPY plays a significant role in the management of head and neck cancer. Tumors in the oral cavity, pharynx, and larynx in all stages of the disease may be amenable to radiation. The goals of treatment may be curative, palliative, or on an adjuvant basis when combined with either surgery or chemotherapy. Several factors contribute to the importance of radiation in the treatment of these cancers. The majority of head and neck cancers are squamous cell cancers arising from the surface epitbelium. Squamous cell cancers are relatively radiosensitive. Radiation is a local treatment for cancer as it is tumoricidal only in the area encompassed by the radiation fields. It is therefore important in treating head and neck cancer which, although it does disseminate, causes most of its morbidity by local extension and invasion. Thus, the primary lesion and lymph nodes can be treated with conventional radiation. ’ The role of radiation therapy in the management of head and neck cancer will be discussed.